BioProgress
This article was originally published in The Rose Sheet
Executive Summary
XGel gelatine-free capsule marketer signs agreement with Nottingham, England-based Boots Healthcare, companies announce Oct. 20. Boots firm will use Atlanta-based BioProgress' animal-free, one-piece soft capsule technology under terms of the deal. Partnership marks BioProgress' second with a British firm, following a summer agreement with Peter Black Healthcare. BioProgress also developing environmentally friendly material for sanitary napkins and diapers, company says. Boots' U.S. subsidiary recently acquired the Clearasil anti-acne line from Procter & Gamble (1"The Rose Sheet" Oct. 23, p. 3)
You may also be interested in...
Boots Healthcare Gains Access To U.S. Market Through Clearasil Buy
Boots Healthcare International views its acquisition of the Clearasil acne prevention and treatment brand as a possible springboard for creating an OTC drug marketing presence in the U.S.
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle